- Home
- IVVD vs BEDU Comparison
IVVD vs BEDU Comparison
Compare IVVD & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- BEDU
- Stock Information
- Founded
- IVVD 2020
- BEDU 1994
- Country
- IVVD United States
- BEDU United Kingdom
- Employees
- IVVD N/A
- BEDU N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- BEDU Other Consumer Services
- Sector
- IVVD Health Care
- BEDU Real Estate
- Exchange
- IVVD Nasdaq
- BEDU Nasdaq
- Market Cap
- IVVD 63.4M
- BEDU 54.0M
- IPO Year
- IVVD 2021
- BEDU 2017
- Fundamental
- Price
- IVVD $0.52
- BEDU $1.80
- Analyst Decision
- IVVD Strong Buy
- BEDU
- Analyst Count
- IVVD 3
- BEDU 0
- Target Price
- IVVD $3.85
- BEDU N/A
- AVG Volume (30 Days)
- IVVD 1.2M
- BEDU 1.2K
- Earning Date
- IVVD 08-14-2025
- BEDU 09-02-2025
- Dividend Yield
- IVVD N/A
- BEDU N/A
- EPS Growth
- IVVD N/A
- BEDU N/A
- EPS
- IVVD N/A
- BEDU N/A
- Revenue
- IVVD $46,210,000.00
- BEDU $224,321,752.00
- Revenue This Year
- IVVD $345.16
- BEDU N/A
- Revenue Next Year
- IVVD $161.08
- BEDU N/A
- P/E Ratio
- IVVD N/A
- BEDU N/A
- Revenue Growth
- IVVD 1941.08
- BEDU N/A
- 52 Week Low
- IVVD $0.35
- BEDU $1.35
- 52 Week High
- IVVD $2.74
- BEDU $2.19
- Technical
- Relative Strength Index (RSI)
- IVVD 32.49
- BEDU 61.35
- Support Level
- IVVD $0.48
- BEDU $1.65
- Resistance Level
- IVVD $0.65
- BEDU $1.91
- Average True Range (ATR)
- IVVD 0.06
- BEDU 0.02
- MACD
- IVVD -0.03
- BEDU 0.01
- Stochastic Oscillator
- IVVD 11.35
- BEDU 45.45
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.